HIV type-1 (HIV-1) is characterised by an extensive genetic heterogeneity originating from the high mutation and recombination rates of the reverse transcriptase (RT) enzyme combined with a high turnover rate [1] . Phylogenetically, HIV-1 viruses are classified into three genetic groups, major (M), outlier (O) and non-M, non-O (N). Within group M, nine subtypes or clades are recognised, designated by the letters A-D, F-H, J and K, as well as 14 circulating recombinant forms (CRFs) [2] . Subtype B is the most prevalent genetic form in Western and Central Europe, North America and Australia; subtype C is the predominant genetic form in India, Eastern and South Africa; and some CRFs play important roles in regional epidemics, for example, CRF01_AE in Southeast Asia. Although almost all studies on drug susceptibility of HIV-1 have been performed in developed countries where subtype B still dominates the epidemic, this subtype only accounts for 12% of global infections. In total, 50% of prevalent HIV-1 infections and 47% of all new HIV-1 infections occur with subtype C, and CRFs account for 18% of incident infections [3] . In addition, the prevalence of other subtypes is increasing in developed countries [4] [5] [6] , which, in Europe, has been linked to immigration and strong relationships with former colonies [7] [8] [9] [10] .
Several studies have demonstrated that different HIV-1 subtypes are associated with different patterns and rates of emerging resistance to antiretrovirals (ARVs) [11] [12] [13] [14] [15] [16] [17] [18] . Differential resistance between subtypes has been well-studied in the presence of the protease inhibitor (PI) nelfinavir (NFV), where distinct
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pathways to resistance and different levels of resulting drug susceptibility have been identified for subtypes B, C and G [19] [20] [21] . In addition, similarities in the effects of mutations between subtypes have also been observed [22] . The high genetic variability of HIV-1 and resulting polymorphisms between subtypes might therefore have important implications for HIV-1 pathogenesis, transmission, diagnosis, treatment and vaccine development [23, 24] . Darunavir (DRV) is an HIV-1 PI with broad-spectrum in vitro ARV activity against both wild-type virus and multidrug-resistant HIV-1 strains [25] . DRV with lowdose ritonavir (DRV/r) has demonstrated ARV efficacy and tolerability in clinical trials in a range of HIV-1-infected patients [26] [27] [28] , and is approved for use in treatment-naive and treatment-experienced patients in several countries [29, 30] .
AntiRetroviral Therapy with TMC114 ExaMined In naive Subjects (ARTEMIS; TMC114-C211) is an ongoing global, Phase III trial assessing the efficacy and safety of DRV/r 800/100 mg once daily versus lopinavir/ritonavir (LPV/r) 800/200 mg (total daily dose) in treatment-naive, HIV-1-infected adult patients. In the primary week 48 per-protocol analysis, 84% of DRV/rand 78% of LPV/r-treated patients achieved a viral load of HIV-1 RNA<50 copies/ml (estimated difference 5.6%; 95% confidence interval [CI] -0.1-11%; P-value for non-inferiority P<0.001), with identical results in the intent-to-treat (ITT) analysis [31] . These results were confirmed by the week 96 analysis, where virological response with DRV/r was statistically non-inferior and superior to LPV/r [28] .
A wide diversity of HIV-1 subtypes was encountered in the population enrolled in the ARTEMIS trial, providing an important opportunity to study the effect of HIV-1 subtype on the efficacy of DRV/r-and LPV/rcontaining regimens. Here, we report, using a broad panel of primary isolates, on the activity of DRV across different HIV-1 subtypes in vitro, and on virological and immunological responses to DRV/r and LPV/r in treatment-naive patients.
Methods

HIV type-1 protease inhibitors
Amprenavir, atazanavir, indinavir, LPV, NFV and saquinavir were extracted from commercial formulations. DRV and tipranavir were produced as previously reported [32, 33] .
HIV type-1 subtyping 
In vitro antiviral activity
In vitro antiviral activity of DRV was assessed in freshly isolated human peripheral blood mononuclear cells (PBMCs) against a panel of 25 HIV-1 primary isolates composed of at least three viruses from each of the group M subtypes (A, B, C, D, E, F and G), as well as three isolates from HIV-1 group O. Serial twofold dilutions of DRV were added in triplicate to phytohaemagglutinin-stimulated PBMCs, pooled from at least two normal healthy donors, in 96-well plates containing 5.0×10 4 cells/well in a final volume of 200 µl. Test viruses were added to the cell cultures at a multiplicity of infection (MOI) of ±0.1. After 6 days of culture, RT activity was quantified in the culture supernatants, as previously described [35] . Phenotypes of baseline plasma samples from ARTEMIS were determined using Antivirogram ® (Virco BVBA).
ARTEMIS study design and patient population
In ARTEMIS, treatment-naive, HIV-1-infected adult patients with HIV-1 RNA≥5,000 copies/ml were randomised to receive DRV/r 800/100 mg once daily (n=343) or LPV/r 800/200 mg total daily dose (n=346), together with a fixed-dose combination of tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg once daily.
Viral load determination
Plasma HIV-1 RNA levels were measured using the Roche Amplicor HIV-1 Monitor assay, version 1.5 or the Roche UltraSensitive method, version 1.5 (Roche Molecular Systems, Branchburg, NJ, USA).
Statistical analyses
The primary efficacy analysis of the ARTEMIS trial at week 48 was based on the per-protocol population to test for non-inferiority in virological response (viral load <50 HIV-1 RNA copies/ml) between DRV/r and LPV/r [31] . In the present report, analyses of virological and immunological response by subtype were performed on the ITT population from the primary efficacy analysis of the ARTEMIS trial (the difference between the per-protocol and ITT populations was three patients, all of whom were excluded from the DRV/r group). At the time of analysis, all patients had reached week 48 of treatment or discontinued earlier.
Virological response (defined as <50 HIV-1 RNA copies/ml) at week 48 was determined using the timeto-loss of virological response (TLOVR) algorithm.
Immunological response (change in CD4 + T-cell count from baseline) at week 48 was determined using the non-completer status equals failure imputation algorithm. Baseline disease characteristics and virological and immunological responses at week 48 were summarised by subtype and by treatment arm. Comparison of the in vitro susceptibility to PIs by subtype was carried out using analysis of variance (ANOVA) comparing the mean baseline log 10 (fold change [FC] ) and performing pairwise comparisons using the TukeyKramer method.
Results
In vitro antiviral activity of DRV against primary HIV type-1 isolates from group M and group O
The antiviral activity of DRV was assessed in freshly isolated human PBMCs against a panel of 25 HIV-1 primary isolates, composed of at least three viruses from each of the group M subtypes (A-G), as well as three isolates from HIV-1 group O. DRV demonstrated high levels of antiviral activity against all of these HIV-1 primary isolates, ranging from <0.10 to 4.28 nM, and a median 50% effective concentration (EC 50 ) of 0.52 nM ( Table 1) .
Effect of HIV type-1 subtype on virological outcome to DRV/r in ARTEMIS
The majority (61%) of patients participating in ARTEMIS were infected with HIV-1 subtype B (Table 2 ; subtype data were not available for one patient from each treatment group). Other prevalent subtypes found were subtype C (13%) and subtype CRF01_AE (17%); 9% of patients harboured other subtypes. HIV-1 subtype B was found primarily in patients in the Americas, Europe and Australia; subtype C was found primarily in Africa and subtype CRF01_AE was found in Europe, Australia and Asia (Figure 1) .
The in vitro susceptibility to DRV and marketed PIs of baseline plasma samples from ARTEMIS was determined using Antivirogram ® and analysed by HIV-1 subtype (Tables 3 and 4 were statistically significant (P<0.0001) for all PIs evaluated, including LPV. The baseline disease characteristics by subtype for both treatment arms in ARTEMIS are shown in Table 5 . The 13 subtypes other than B, C and CRF01_ AE were grouped together because of low patient numbers (approximately 30 patients overall in each treatment arm). The distribution of subtypes was comparable between the DRV/r and LPV/r treatment arms. Baseline viral load and CD4 + T-cell counts were similar between patients with different viral subtypes across both treatment arms.
The virological response (defined as viral load <50 HIV-1 RNA copies/ml) at week 48 in both treatment arms was determined using the ITT-TLOVR algorithm and summarized by HIV-1 subtype (Figure 2A Overall, 84% of patients in the DRV/r arm achieved viral loads <50 HIV-1 RNA copies/ml at week 48 versus 78% of patients in the LPV/r arm (difference 5.3%; 95% CI -0.5-11.2%). The response rates in both treatment arms were comparable across patient groups harbouring subtypes B, C and CRF01_AE (81%, 87% and 85% for the DRV/r arm, and 78%, 82% and 82% for the LPV/r arm, respectively). Higher numerical response rates were observed for patients infected with subtypes C and CRF01_AE relative to subtype B in the DRV/r treatment arm; this trend was also observed in the LPV/r arm. Although the subgroup of patients with other subtypes was limited in terms of patient numbers and diverse in terms of the number of different subtypes, the response rate was higher in the DRV/r arm compared with the LPV/r arm for this group of non-B subtypes, consistent with what was observed in the subgroup of patients with subtype B. The immunological responses (ITT, non-completer status equals failure) were summarized at week 48 by 
Discussion
The results from in vitro experiments on the antiviral activity of DRV against primary HIV-1 isolates in PBMCs (median EC 50 0.52 nM) showed that DRV is highly active against group M and group O primary isolates of HIV-1 from diverse geographical origins. This observation was confirmed in clinical isolates from treatment-naive patients participating in the ARTEMIS trial, where DRV displayed a high in vitro antiviral activity against subtype B and the studied non-B subtype HIV-1 recombinant clinical isolates. These results are in agreement with the observations from Poveda et al. [36] , who showed that all HIV-1 subtypes (including subtypes A, C, CRF01_AE, CRF02_AG, CRF12_BF, CRF14_BG, F and G) from 29 drug-naive, HIV-1-infected individuals were fully susceptible to DRV in comparison with 93% to tipranavir.
The broad in vitro susceptibility to DRV of clinical isolates from ARV-naive patients enrolled in the ARTEMIS study across subtypes was also reflected in the consistency of response rates observed. In ARTEMIS, DRV/r 800/100 mg once daily was highly effective overall (84% response rate for viral load <50 copies/ml [ITT-TLOVR]) and equally effective irrespective of the HIV-1 subtype with response rates of 81%, 87% and 85% for patient groups infected with subtypes B, C and CRF01_AE, respectively. This trend was also observed in the LPV/r arm. The numerically higher overall response rates in the DRV/r arm (84%) compared with the LPV/r arm (78%) were also observed across all studied HIV-1 subtype groups, with response rates in the LPV/r arm of 78%, 82% and 82% for patient groups with subtypes B, C and CRF01_AE, respectively. The information derived for the group of other HIV-1 subtypes was less conclusive because these subgroups of patients were small and highly diverse (31 and 32 patients in the DRV/r and LPV/r arm, respectively, containing 13 different subtypes); however, the response rate for this group was, again, higher in the DRV/r arm (94%) than in the LPV/r arm (72%).
In agreement with the absence of an effect of HIV-1 subtype on virological response to DRV/r and LPV/r, no clinically relevant differences on immunological response to either PI were observed in ARTEMIS. Our findings are in line with other reports concluding that HIV-1 subtype does not appear to affect efficacy to first-line therapy and that currently available protease and RT inhibitors are equally active across all HIV-1 subtypes [37] [38] [39] [40] . However, for several of these analyses, the influence of HIV-1 subtype on the virological outcome was studied independently of the type of ARV therapy, with no specific data on the influence of subtype on the efficacy of individual protease and RT inhibitors. In addition, limited data are available concerning baseline viral susceptibility and clinical outcome to ARV therapy in patients infected with non-B subtypes; this also represents a limitation of our analysis because of low numbers of patients infected with non-B subtypes other than C and CRF01_AE.
Individual HIV-1 subtypes are distributed among different populations with varying characteristics and behaviours; however, the extent to which differences in virological outcome between subtypes are driven by adherence to ARV medication, rather than subtypedependent drug susceptibility, is not clear. A recent study found no differences in adherence based on ethnicity or subtype despite significantly higher rates of CD4 + T-cell count reduction and virological rebound in patients with subtype D relative to other subtypes (A, B, C and CRF02_AG) [41] , suggesting that variations in subtype-dependent susceptibility might have played the predominant role in influencing treatment outcomes in this case. This was in line with a larger study showing differences in rebound risk between subtypes were maintained after accounting for non-adherence [42] . Another report concluded that the differential development of resistance mutations between subtypes during NFV treatment was more likely to be influenced by subtype-dependent genetic polymorphisms rather than adherence patterns, on account of similar results being observed across populations with known socioeconomic and behavioural differences [19] . Conversely, in a subanalysis examining prognostic factors associated with virological response to LPV/r monotherapy in the recent MONARK trial, HIV-1 subtype B was significantly associated with achieving a virological response, versus non-B subtypes [43] . Moreover, adherence to study medication was lower in patients infected with non-B than B subtypes, and was itself identified as an important factor contributing to the achievement of virological response in different subtypes [43] . The conclusions of this study are limited by small patient numbers and the monotherapy-based regimen studied. Interestingly, however, in the primary ARTEMIS analysis, lower adherence to study medication affected virological response with LPV/r to a greater extent than with DRV/r [31] . Because HIV-1 subtype did not appear to affect virological response rates with LPV/r in the present analysis, the influence of adherence relative to subtype in this setting is unclear.
Interestingly, for all PIs evaluated in the present analysis, a higher in vitro susceptibility among subtype C or CRF01_AE recombinant isolates compared with subtype B isolates was observed. Other groups have reported that subtype C and also CRF02_AG recombinant viruses from drug-naive patients show in vitro hypersusceptibility to PIs [44] , including LPV [45] .
Although determining the precise clinical implications of these in vitro observations requires carefully designed studies, our findings suggest that such a phenomenon could be, in part, responsible for the higher numerical response rates seen in the DRV/r and LPV/r arms in patients infected with the non-subtype B HIV-1 isolates we studied.
In conclusion, for the HIV-1 subtypes we studied, in vitro susceptibility and virological outcome to DRV/r and LPV/r in treatment-naive patients in the ARTEMIS trial was independent of subtype. These findings confirm the broad spectrum activity of DRV/r and LPV/r against HIV-1.
